6 citations
,
May 2018 in “Zeitschrift für Rheumatologie” A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
78 citations
,
January 2013 in “Dermatology Online Journal” Hidradenitis suppurativa is linked to various diseases like obesity, depression, arthritis, and Crohn's disease, but often occurs alone.
7 citations
,
August 2024 in “Journal of Functional Biomaterials” PRP injections improve knee function better than other treatments for osteoarthritis.
October 2023 in “Benha Journal of Applied Sciences” Methotrexate and vitamin D3 are potentially more effective and safer than triamcinolone for treating localized alopecia areata.
December 2022 in “Research Square (Research Square)” A multi-tiered treatment approach is crucial for managing hidradenitis suppurativa in patients with intellectual and developmental disorders.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
2 citations
,
February 2022 in “Journal of Pharmacy and Pharmacology” Methotrexate-loaded formulations showed promise for psoriasis treatment but need careful evaluation.
April 2023 in “Journal of Investigative Dermatology” PX-12 may help treat psoriasis by blocking inflammation and cell death.
June 2023 in “Fundamental & clinical pharmacology” JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.
November 2023 in “Journal of Investigative Dermatology” Adipose stem cell exosomes may effectively treat atopic dermatitis by reducing inflammation and improving skin health.
July 2025 in “Journal of Cosmetic Dermatology” Triamcinolone is more effective than methotrexate for treating localized alopecia areata.
October 1984 in “Immunology Today”
10 citations
,
September 1997 in “Molecular carcinogenesis” Mirex seems to promote a unique group of skin cells different from those affected by another tumor promoter, TPA.
10 citations
,
July 2002 in “Australasian Journal of Dermatology” Careful management of blood thinners is crucial for lupus patients with APS.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
July 2024 in “Journal of Investigative Dermatology” Biosimilars lower costs but don't significantly improve access.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
69 citations
,
December 2006 in “Archives of dermatology” Adalimumab may cause severe hair loss in some patients.
March 2026 in “Food Science & Nutrition” Arachis hypogaea L. root extract reduces prostate enlargement and inflammation in mice.
January 2023 in “Journal of Plastic Surgery and Hand Surgery” Autogenic PRP improves graft viability more than xenogenic PRP, but both are effective.
June 2020 in “Annals of the Rheumatic Diseases” Patients need better information about the risks of long-term steroid use.
March 2026 in “Dermatology Online Journal” Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
39 citations
,
January 2012 in “Dermatology” Combining high-dose corticosteroids with methotrexate may be effective and safe for severe alopecia areata.
May 2015 in “The Journal of Dermatology” Alopecia areata and polymyalgia rheumatica may be linked autoimmune conditions.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.
October 2021 in “Dermatology reports” The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.
September 2013 in “Oncology Times” Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
December 2025 in “Journal of Human Immunity” JAK inhibitors may help improve symptoms in adults with APECED.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.